Microchip Technology (NasdaqGS:MCHP) 1% Dip With Board Shift As Rango Exits

Microchip Technology (NasdaqGS:MCHP) saw a price decline of 0.65% over the past month, amidst a flurry of developments. Recently, the company unveiled the PIC32A family of microcontrollers and a cost-effective in-circuit debugger, signaling a push to strengthen its position in the semiconductor industry. During the same period, the broader market faced challenges, with the S&P 500 entering a correction phase driven by economic uncertainties stemming from policy changes and tariff concerns. Despite experiencing a remarkable rally, major indexes ended on a lower note for the fourth consecutive week. Although individual technology stocks like Nvidia and Palantir led temporary recoveries, market volatility persisted. In contrast to the broader technology sector's gains, reflected in the VanEck Semiconductor ETF's 3% increase, MCHP's relatively minor decline could be attributed to market conditions rather than company-specific developments. Meanwhile, Robert A. Rango’s exit from the board suggests potential shifts within the governance framework.

Evaluate Microchip Technology's prospects by accessing our earnings growth report.

NasdaqGS:MCHP Earnings Per Share Growth as at Mar 2025
NasdaqGS:MCHP Earnings Per Share Growth as at Mar 2025

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 23 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Over the last five years, Microchip Technology's total shareholder return, including share price and dividends, rose 95.82%. This performance underscores significant growth and resilience amidst varied market conditions. While Microchip's earnings have grown by 21.8% annually over this period, recent developments such as the introduction of the PIC32A family of microcontrollers in March 2025 and the PICkit Basic In-Circuit Debugger highlight the company’s commitment to expanding its semiconductor offerings. The release of these innovative products supports applications in automotive, industrial, and data center sectors, potentially enhancing long-term demand.

In the most recent year, however, Microchip's performance has lagged, underperforming both the US Semiconductor industry return of 16.5% and the broader market's 9.5% gain. Despite these challenges, earnings are expected to grow at a significant rate of over 42% annually in the coming years, with a forecasted revenue growth higher than that of the US market. However, the company's Price-To-Earnings Ratio remains high, indicating it may be perceived as expensive relative to the industry averages.

Got skin in the game with Microchip Technology? Elevate the management of your position by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:MCHP

Microchip Technology

Develops, manufactures, and sells smart, connected, and secure embedded control solutions in the Americas, Europe, and Asia.

High growth potential and fair value.

Advertisement

Weekly Picks

CE
Ceazar
SPAI logo
Ceazar on Sparc AI ·

When GPS fails: this small cap is fixing a $54B drone problem

Fair Value:CA$5.2554.7% undervalued
110 users have followed this narrative
0 users have commented on this narrative
24 users have liked this narrative
BL
BlackGoat
IREN logo
BlackGoat on IREN ·

IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers

Fair Value:US$71.4859.0% undervalued
213 users have followed this narrative
8 users have commented on this narrative
32 users have liked this narrative
HE
HedgeY
ARM logo
HedgeY on Arm Holdings ·

The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?

Fair Value:US$43047.7% undervalued
20 users have followed this narrative
1 users have commented on this narrative
6 users have liked this narrative
HI
Hidden_Rock_Capital
FISV logo
Hidden_Rock_Capital on Fiserv ·

Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings

Fair Value:US$119.9953.6% undervalued
26 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

AS
AstrisCorporateAdvisory
3132 logo
AstrisCorporateAdvisory on Macnica Holdings ·

Core business remains firm, new growth initiative delayed

Fair Value:JP¥2.61k19.7% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DI
divine_4y1uv
AIIO logo
divine_4y1uv on Robo.ai ·

Robo.ai Appoints Former INTERPOL President H.E. Dr. Ahmed Naser Al-Raisi as Chairman of Its Subsidiary Alif Holding

Fair Value:US$0.0027108.0k% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BE
PRCT logo
Betsareoff on PROCEPT BioRobotics ·

PROCEPT BioRobotics sees 17.69% revenue growth and aims for 12.94% profit margin

Fair Value:US$25.2629.2% undervalued
4 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28032.1% undervalued
211 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.0% undervalued
97 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6510.2% undervalued
74 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0